argenx to Acquire Unnatural Products for ~$1.15B to Expand Macrocyclic Peptide Capabilities

Shots: argenx has entered into a definitive agreement to acquire Unnatural Products (UNP), adding UNP’s macrocyclic peptide discovery engine to its antibody engineering capabilities for developing oral or long-acting medicines in immune-mediated diseases argenx, which already holds a minority stake in UNP, will acquire all remaining shares for $550M upfront in cash & up to $595M in development & regulatory milestones, for a total potential value of ~$1.15B; the deal is expected to close by YE’26 The acquisition builds on the companies’ 2-year multi-target research collaboration; UNP will continue to operate from Santa Cruz, CA as argenx’s peptide discovery hub Ref: GlobeNewswire  |   Image: argenx | Unnatural Products  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post argenx to Acquire Unnatural Products for ~$1.15B to Expand Macrocyclic Peptide Capabilities appeared first on PharmaShots.